Open AccessRavulizumab (Ultomiris)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.319
Subject(s) - reimbursement , paroxysmal nocturnal hemoglobinuria , medicine , family medicine , business , political science , health care , law
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses ravulizumab (Ultomiris), 10 mg/mL concentrate for solution for infusion.
Indication: For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom